Browsing by Author "Boyer, Olivia (8509255100)"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope(2023) ;Groothoff, Jaap W. (57210794658) ;Metry, Ella (58807050100) ;Deesker, Lisa (57700918600) ;Garrelfs, Sander (56623164000) ;Acquaviva, Cecile (6602681882) ;Almardini, Reham (56002280600) ;Beck, Bodo B. (7201775218) ;Boyer, Olivia (8509255100) ;Cerkauskiene, Rimante (12777362300) ;Ferraro, Pietro Manuel (25724310200) ;Groen, Luitzen A. (25924896200) ;Gupta, Asheeta (56941152200) ;Knebelmann, Bertrand (7004605792) ;Mandrile, Giorgia (16417413800) ;Moochhala, Shabbir S. (57209048730) ;Prytula, Agnieszka (35225249500) ;Putnik, Jovana (14008113300) ;Rumsby, Gill (7006099271) ;Soliman, Neveen A. (55212159700) ;Somani, Bhaskar (57218701740)Bacchetta, Justine (23491355700)Primary hyperoxaluria (PH) is an inherited disorder that results from the overproduction of endogenous oxalate, leading to recurrent kidney stones, nephrocalcinosis and eventually kidney failure; the subsequent storage of oxalate can cause life-threatening systemic disease. Diagnosis of PH is often delayed or missed owing to its rarity, variable clinical expression and other diagnostic challenges. Management of patients with PH and kidney failure is also extremely challenging. However, in the past few years, several new developments, including new outcome data from patients with infantile oxalosis, from transplanted patients with type 1 PH (PH1) and from patients with the rarer PH types 2 and 3, have emerged. In addition, two promising therapies based on RNA interference have been introduced. These developments warrant an update of existing guidelines on PH, based on new evidence and on a broad consensus. In response to this need, a consensus development core group, comprising (paediatric) nephrologists, (paediatric) urologists, biochemists and geneticists from OxalEurope and the European Rare Kidney Disease Reference Network (ERKNet), formulated and graded statements relating to the management of PH on the basis of existing evidence. Consensus was reached following review of the recommendations by representatives of OxalEurope, ESPN, ERKNet and ERA, resulting in 48 practical statements relating to the diagnosis and management of PH, including consideration of conventional therapy (conservative therapy, dialysis and transplantation), new therapies and recommendations for patient follow-up. © 2023, Springer Nature Limited. - Some of the metrics are blocked by yourconsent settings
Publication Results in the ESPN/ERA-EDTA Registry suggest disparities in access to kidney transplantation but little variation in graft survival of children across Europe(2020) ;Bonthuis, Marjolein (36130877600) ;Cuperus, Liz (57218099301) ;Chesnaye, Nicholas C. (45960892700) ;Akman, Sema (7005050235) ;Melgar, Angel Alonso (6603128415) ;Baiko, Sergey (56060108700) ;Bouts, Antonia H. (6602108355) ;Boyer, Olivia (8509255100) ;Dimitrova, Kremena (57202156324) ;Carmo, Carmen do (57205574491) ;Grenda, Ryszard (13606275800) ;Heaf, James (7004499802) ;Jahnukainen, Timo (6602193869) ;Jankauskiene, Augustina (6603408774) ;Kaltenegger, Lukas (57204168960) ;Kostic, Mirjana (56247970900) ;Marks, Stephen D. (8889557300) ;Mitsioni, Andromachi (6508179149) ;Novljan, Gregor (6505776027) ;Palsson, Runolfur (6601953759) ;Parvex, Paloma (6507082334) ;Podracka, Ludmila (7004838770) ;Bjerre, Anna (6701773175) ;Seeman, Tomas (7101761683) ;Slavicek, Jasna (56256009000) ;Szabo, Tamas (56267946500) ;Tönshoff, Burkhard (7005057465) ;Torres, Diletta D. (8541300400) ;Van Hoeck, Koen J. (14420346800) ;Ladfors, Susanne Westphal (57204619433) ;Harambat, Jérôme (34879883900) ;Groothoff, Jaap W. (57210794658)Jager, Kitty J. (55382765700)One of the main objectives of the European health policy framework is to ensure equitable access to high-quality health services across Europe. Here we examined country-specific kidney transplantation and graft failure rates in children and explore their country- and patient-level determinants. Patients under 20 years of age initiating kidney replacement therapy from January 2007 through December 2015 in 37 European countries participating in the ESPN/ERA-EDTA Registry were included in the analyses. Countries were categorized as low-, middle-, and high-income based on gross domestic product. At five years of follow-up, 4326 of 6909 children on kidney replacement therapy received their first kidney transplant. Overall median time from kidney replacement therapy start to first kidney transplantation was 1.4 (inter quartile range 0.3-4.3) years. The five-year kidney transplantation probability was 48.8% (95% confidence interval: 45.9-51.7%) in low-income, 76.3% (72.8-79.5%) in middle-income and 92.3% (91.0-93.4%) in high-income countries and was strongly associated with macro-economic factors. Gross domestic product alone explained 67% of the international variation in transplantation rates. Compared with high-income countries, kidney transplantation was 76% less likely to be performed in low-income and 58% less likely in middle-income countries. Overall five-year graft survival in Europe was 88% and showed little variation across countries. Thus, despite large disparities transplantation access across Europe, graft failure rates were relatively similar. Hence, graft survival in low-risk transplant recipients from lower-income countries seems as good as graft survival among all (low-, medium-, and high-risk) graft recipients from high-income countries. © 2020 International Society of Nephrology
